1) Strategy & Leadership
- Aflac reported a strong start to 2026, with net earnings per diluted share of $1.98 and adjusted earnings of $1.75.
- The company continues to execute its marketing and sales transformation strategy in Japan, which has driven strong sales momentum, particularly in new medical and cancer insurance products.
- Leadership in Japan, including Deputy President Shinsuke Mary Moto and Chief Marketing Officer Yumi Saito, has been pivotal in achieving these results.
- Aflac is focused on maintaining strong persistency rates while adding new premiums to offset lapses and paid-up policies.

2) Financial & Segment Results
- Aflac Japan experienced a 25.5% increase in sales for Q1, driven by new products like Onsen Tallett and Miraito.
- In the U.S., sales increased by 2.9% year-over-year, with a net earned premium growth of 3.5%.
- The adjusted return on equity (ROE) was 12.8%, with 16.4% excluding foreign currency remeasurement.
- The benefit ratio for Japan was 62.9%, down 290 basis points year-over-year, while the U.S. benefit ratio was 47.2%, 50 basis points lower than the previous year.

3) Problems / Headwinds
- Aflac Japan's underlying earned premiums declined by 1.3%, indicating challenges in premium growth despite strong sales.
- The company noted an uptick in lapse and reissue activity, particularly among younger policyholders, which could impact future persistency.
- The Corporate & Other segment reported breakeven pretax adjusted earnings, down from a $43 million gain last year, due to lower investment income and higher operating costs.

4) Operational or Product Plans
- Aflac plans to continue promoting third sector protection products to younger customers, leveraging its broad distribution channels.
- The company is optimistic about the potential for external reinsurance deals in Japan, which could enhance growth and diversify earnings streams.
- Aflac is focused on improving agent recruitment and productivity in the U.S. to drive growth in its core business, which has been flat recently.

5) Guidance & Outlook / Investor Angle
- Aflac aims for Japan sales to reach approximately JPY 80 billion in 2026, up from JPY 74 billion in 2025.
- The company maintains a strong capital position with an estimated regulatory ESR of 227% and plans to continue returning capital to shareholders through dividends and share repurchases.
- The guidance for the U.S. benefit ratio remains at 42% to 52%, with expectations for improvement in the latter half of the year.

Bottom line: Aflac's strong sales growth in Japan and stable performance in the U.S. position the company well for continued shareholder value creation, despite some challenges in premium growth and persistency. The strategic focus on reinsurance and product innovation could further enhance growth prospects.